NCT06305754
Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)
Active, Not Recruiting
PHASE3Ages 18+InterventionalTreatmentMerck Sharp & Dohme LLC
~551 participants
Updated 2026-08-03 on ClinicalTrials.gov
What's tested:Sacituzumab tirumotecanPemetrexedCarboplatinH1 Receptor AntagonistH2 Receptor AntagonistAcetaminophen (or equivalent)
At a glance
Recruiting sites
0 of 156 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Overall Survival (OS)
Measured over Up to approximately 51 months
Conditions
Where it's being run
156 sites across 100 statesTaiwan9
California6
Japan6
Turkey (Türkiye)5
Kyonggi-do4
South Korea4
Texas3
Zhejiang3
Study leadership
- Medical Director · STUDY_DIRECTOR · Merck Sharp & Dohme LLC
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Histologically or cytologically confirmed diagnosis of advanced-stage nonsquamous non-small cell lung cancer (NSCLC).
Participants who have adverse events (AEs) due to previous anticancer therapies must have recovered to Grade ≤1 or baseline.
Participants who are Hepatitis B surface antigen (HBsAg) positive are eligible if they have received Hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load.
Participants with history of Hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable.
Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on antiretroviral therapy.
Life expectancy of at least 3 months.
Exclusion
Predominantly squamous cell histology NSCLC.
History of second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 3 years.
Grade ≥2 peripheral neuropathy.
History of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing.
Active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease.
Uncontrolled, or significant cardiovascular disease or cerebrovascular disease.
Received prior radiotherapy within 2 weeks of start of study intervention, or radiation-related toxicities, requiring corticosteroids.
Received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines are allowed.
Received radiation therapy to the lung that is \>30 Gray within 6 months of the first dose of study intervention.
Known active central nervous system metastases and/or carcinomatous meningitis.
Active infection requiring systemic therapy.
History of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease.
HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease.
Concurrent active HBV and HCV infection.
History of allogeneic tissue/solid organ transplant.
Participants who have not adequately recovered from major surgery or have ongoing surgical complications.
What this trial measures
- Overall Survival (OS)Up to approximately 51 months
Overall survival is defined as the time from randomization to death due to any cause. Overall survival for all randomized participants will be reported.